Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
238
Total raised
£3.1B
disclosed amounts
This month
£7.8M
raised so far
The financing round was backed by investors including Elkstone Capital, SciFounders, and Faber.
"Our mission is to revolutionise the user experience of healthcare. We do that by building medical devices with a patient-first approach, and focusing on the needs that truly matter to patients. This funding round will allow us to complete first in patient clinical trials of our innovative Lily Device, and accelerate our path to market launch and patient impact in 2024"
Forward Partners led the seed plus financing to help the healthcare technology firm scale its operations in the United States and Europe.
"This investment enables us to focus on the growth of our customer base in the US, develop our customer success strategy and expand our AI capabilities to further enable discovery in healthcare. We are delighted to welcome Forward Partners to the board and feel their commercial insights will help drive the business to increased success."
The funding round was led by Archangels to support human trials of the BioCaptis device.
"BIOCAPTIVA is at the forefront of developing technology to transform liquid biopsy testing in cancer management. We are pleased to have raised these additional funds as the company enters its next stage of development, with the BioCaptis beginning its first in human trials. These trials will allow us to generate important data before the end of 2022. This will be a key step before starting regulatory trials in 2023 as we move towards our goal of unleashing the full potential of liquid biopsy in cancer management to improve patient outcomes."
Leafy Tunnel led the Series A round to fund expansion into multiple European markets.
"It was critical for Lyphe to raise enough funds to execute on our scale-up plans and be in control of our destiny. We are fortunate to be leaders in our primary market with a very clear growth plan, and as such we have attracted the very best investors into this round from US, Europe and UK. Leafy Tunnel sees us step into venture capital, and we are honoured to have them on the cap table and supporting our vision for international growth, alongside Sharp Capital and all other new and old shareholders."
Foresight Williams Technology led the oversubscribed round alongside several regional and specialist investors.
"We are excited to announce our support for such a forward thinking and innovative business. Nebu~Flow’s development of delivery mechanisms tailored to specific drugs represents an opportunity to expand the market and improve patient outcomes. Foresight Williams Technology’s expertise will offer significant value as the Company develops its products, and we look forward to working with the team at Nebu~Flow during the next stage of their growth."
